Glepaglutide

未知生产厂商

Glepaglutide is under investigation in clinical trial NCT00868660 (Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose).

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

Glepaglutide is under investigation in clinical trial NCT00868660 (Healthy Normal Single Ascending Dose and Crohn's Patient Multiple Ascending Dose).

技术标识符

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

PROCESS FOR FORMULATING COMPOSITIONS COMPRISING GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES
EP 4398872 B1申请人: ZEALAND PHARMA AS优先权: 2021
CN
EP
US
WO
4 件公开
PROCESSES FOR SYNTHESIZING GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES
US 20260116943 A1申请人: ZEALAND PHARMA AS优先权: 2021
CN
EP
US
WO
4 件公开
GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES AND THEIR MEDICAL USES FOR THE TREATMENT OF SHORT BOWEL SYNDROME (SBS)
EP 4572783 A1申请人: ZEALAND PHARMA AS优先权: 2022
EP
WO
2 件公开
FORMULATIONS OF GLUCAGON-LIKE-PEPTIDE 2 (GLP-2) ANALOGUES AND THEIR USES
WO 2025141129 A1申请人: ZEALAND PHARMA AS优先权: 2023
CN
WO
2 件公开
一种Glepaglutide的制备方法
CN 116751278 B申请人: 杭州信海医药科技有限公司优先权: 2023
CN
2 件公开
USE OF GLP-2 ANALOGUES IN PATIENTS WITH RENAL INSUFFICIENCY
US 2024091317 A1申请人: ZEALAND PHARMA AS优先权: 2020
US
Use of GLP-2 analogs in patients with renal insufficiency
CN 116782922 A申请人: ZEALAND PHARMA AS优先权: 2021
CN